Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Dec;31(3-4):593-603.
doi: 10.1007/s10555-012-9374-8.

Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene

Natascia Marino  1 , Joji Nakayama, Joshua W Collins, Patricia S Steeg
Affiliations
Review

Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene

Natascia Marino et al. Cancer Metastasis Rev. 2012 Dec.

Abstract

Metastatic disease is the major cause of death among cancer patients. A class of genes, named metastasis suppressors, has been described to specifically regulate the metastatic process. The metastasis suppressor genes are downregulated in the metastatic lesion compared to the primary tumor. In this review, we describe the body of research surrounding the first metastasis suppressor identified, Nm23. Nm23 overexpression in aggressive cancer cell lines reduced their metastatic potential in vivo with no significant reduction in primary tumor size. A complex mechanism of anti-metastatic action is unfolding involving several known Nm23 enzymatic activities (nucleotide diphosphate kinase, histidine kinase, and 3'-5' exonuclease), protein-protein interactions, and downstream gene regulation properties. Translational approaches involving Nm23 have progressed to the clinic. The upregulation of Nm23 expression by medroxyprogesterone acetate has been tested in a phase II trial. Other approaches with significant preclinical success include gene therapy using traditional or nanoparticle delivery, and cell permeable Nm23 protein. Recently, based on the inverse correlation of Nm23 and LPA1 expression, a LPA1 inhibitor has been shown to both inhibit metastasis and induce metastatic dormancy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Several therapeutic strategies using Nm23-H1 have been reported and tested in in vivo models in order to restore the metastatic suppression property of Nm23. Nm23-H1 expression increased after the treatment with Medroxyprogesterone acetate (MPA) or other natural compounds ( thujone, LMPAB, amentoflavone). Three Nm23-H1 delivery methods, the adeno-associated virus (AAV)- Nm23-H1, the poly-L-lysine-modified iron oxide nanoparticle (IONP-PLL)-Nm23-H1 and the cell permeable Nm23-H1 protein (CP-Nm23), have been reported. Lysophosphatidylcholine receptor 1 (LPA1), a new therapeutic target mediator of metastatic dormancy was identified , based on its inverse correlation to Nm23 expression
See this image and copyright information in PMC

References

    1. Steeg PS, et al. (1988). Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. Cancer Research, 48 (22), 6550–6554. - PubMed
    1. Dearolf CR, Hersperger E, & Shearn A (1988). Developmental consequences of awdb3, a cell-autonomous lethal mutation of Drosophila induced by hybrid dysgenesis. Developmental Biology, 129(1), 159–168. - PubMed
    1. Dearolf CR, et al. (1988). Molecular consequences of awdb3, a cell-autonomous lethal mutation of Drosophila induced by hybrid dysgenesis. Developmental Biology, 129(1), 169–178. - PubMed
    1. Lacombe ML, et al. (2000). The human Nm23/nucleoside diphosphate kinases. Journal of Bioenergetics and Biomembranes, 32 (3), 247–258. - PubMed
    1. Steeg PS, Zollo M, &Wieland T. (2011). A critical evaluation of biochemical activities reported for the nucleoside diphosphate kinase/Nm23/Awd family proteins: opportunities and missteps in understanding their biological functions. Naunyn-Schmiedeberg’s Archives of Pharmacology, 384(4–5), 331–339. - PMC - PubMed

Publication types

Substances